Potential therapeutic system for Alzheimer's disease: Removal of blood Aβs by hemodialzyers and its effect on the cognitive functions of renal-failure patients

Masao Kato, Kazunori Kawaguchi, Sigeru Nakai, Kazutaka Murakami, Hideo Hori, Atsushi Ohashi, Yoshiyuki Hiki, Shinji Ito, Yasunobu Shimano, Nobuo Suzuki, Satoshi Sugiyama, Hiroshi Ogawa, Hiroko Kusimoto, Tatsuro Mutoh, Yukio Yuzawa, Nobuya Kitaguchi

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The pathological changes of Alzheimer's disease include the deposition of amyloid β protein (Aβ) as senile plaques in the brain. We hypothesized that the rapid removal of Aβs from the blood may act as a peripheral Aβ drainage sink from the brain. In this study, the plasma Aβ concentrations and the cognitive functions were investigated for in 57 patients on hemodailysis (69.4 ± 3.8 years), 26 renal-failure patients without hemodialysis (66.6 ± 14.7 years), and 17 age-matched healthy controls (66.6 ± 4.1 years). The concentrations of plasma Aβs increased along with the decline of renal functions. Moreover, the renal-failure patients without hemodialysis and with poorer renal functions showed lower cognitive functions. The plasma concentrations of Aβ1-42 correlated with serum creatinine (P < 0.001) and Mini-Mental-State Examination scores (P = 0.017). The dialyzers effectively removed Aβs in the blood during hemodialysis sessions. The plasma Aβ concentrations showed steady or slightly decreasing along with duration of hemodialysis. The total amount of Aβs removed during a hemodialysis session was calculated to be comparable to the Aβs dissolved in the blood and the cerebrospinal fluid. The MMSE scores of the hemodialysis patients showed no clear decrease in longer hemodialysis duration. Therefore, the therapeutic approach for Alzheimer's disease by removing Aβs from the blood is worthy of further investigation, including whether or not Aβs in the brain decrease.

Original languageEnglish
Pages (from-to)1533-1544
Number of pages12
JournalJournal of Neural Transmission
Volume119
Issue number12
DOIs
Publication statusPublished - 01-12-2012

Fingerprint

Cognition
Renal Insufficiency
Renal Dialysis
Alzheimer Disease
Therapeutics
Brain
Kidney
Serum Amyloid A Protein
Amyloid Plaques
Cerebrospinal Fluid
Drainage
Creatinine
Serum

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Kato, Masao ; Kawaguchi, Kazunori ; Nakai, Sigeru ; Murakami, Kazutaka ; Hori, Hideo ; Ohashi, Atsushi ; Hiki, Yoshiyuki ; Ito, Shinji ; Shimano, Yasunobu ; Suzuki, Nobuo ; Sugiyama, Satoshi ; Ogawa, Hiroshi ; Kusimoto, Hiroko ; Mutoh, Tatsuro ; Yuzawa, Yukio ; Kitaguchi, Nobuya. / Potential therapeutic system for Alzheimer's disease : Removal of blood Aβs by hemodialzyers and its effect on the cognitive functions of renal-failure patients. In: Journal of Neural Transmission. 2012 ; Vol. 119, No. 12. pp. 1533-1544.
@article{363b6efedcc342b7a70a2ceb06f92847,
title = "Potential therapeutic system for Alzheimer's disease: Removal of blood Aβs by hemodialzyers and its effect on the cognitive functions of renal-failure patients",
abstract = "The pathological changes of Alzheimer's disease include the deposition of amyloid β protein (Aβ) as senile plaques in the brain. We hypothesized that the rapid removal of Aβs from the blood may act as a peripheral Aβ drainage sink from the brain. In this study, the plasma Aβ concentrations and the cognitive functions were investigated for in 57 patients on hemodailysis (69.4 ± 3.8 years), 26 renal-failure patients without hemodialysis (66.6 ± 14.7 years), and 17 age-matched healthy controls (66.6 ± 4.1 years). The concentrations of plasma Aβs increased along with the decline of renal functions. Moreover, the renal-failure patients without hemodialysis and with poorer renal functions showed lower cognitive functions. The plasma concentrations of Aβ1-42 correlated with serum creatinine (P < 0.001) and Mini-Mental-State Examination scores (P = 0.017). The dialyzers effectively removed Aβs in the blood during hemodialysis sessions. The plasma Aβ concentrations showed steady or slightly decreasing along with duration of hemodialysis. The total amount of Aβs removed during a hemodialysis session was calculated to be comparable to the Aβs dissolved in the blood and the cerebrospinal fluid. The MMSE scores of the hemodialysis patients showed no clear decrease in longer hemodialysis duration. Therefore, the therapeutic approach for Alzheimer's disease by removing Aβs from the blood is worthy of further investigation, including whether or not Aβs in the brain decrease.",
author = "Masao Kato and Kazunori Kawaguchi and Sigeru Nakai and Kazutaka Murakami and Hideo Hori and Atsushi Ohashi and Yoshiyuki Hiki and Shinji Ito and Yasunobu Shimano and Nobuo Suzuki and Satoshi Sugiyama and Hiroshi Ogawa and Hiroko Kusimoto and Tatsuro Mutoh and Yukio Yuzawa and Nobuya Kitaguchi",
year = "2012",
month = "12",
day = "1",
doi = "10.1007/s00702-012-0844-5",
language = "English",
volume = "119",
pages = "1533--1544",
journal = "Journal of Neural Transmission",
issn = "0300-9564",
publisher = "Springer Verlag",
number = "12",

}

Potential therapeutic system for Alzheimer's disease : Removal of blood Aβs by hemodialzyers and its effect on the cognitive functions of renal-failure patients. / Kato, Masao; Kawaguchi, Kazunori; Nakai, Sigeru; Murakami, Kazutaka; Hori, Hideo; Ohashi, Atsushi; Hiki, Yoshiyuki; Ito, Shinji; Shimano, Yasunobu; Suzuki, Nobuo; Sugiyama, Satoshi; Ogawa, Hiroshi; Kusimoto, Hiroko; Mutoh, Tatsuro; Yuzawa, Yukio; Kitaguchi, Nobuya.

In: Journal of Neural Transmission, Vol. 119, No. 12, 01.12.2012, p. 1533-1544.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Potential therapeutic system for Alzheimer's disease

T2 - Removal of blood Aβs by hemodialzyers and its effect on the cognitive functions of renal-failure patients

AU - Kato, Masao

AU - Kawaguchi, Kazunori

AU - Nakai, Sigeru

AU - Murakami, Kazutaka

AU - Hori, Hideo

AU - Ohashi, Atsushi

AU - Hiki, Yoshiyuki

AU - Ito, Shinji

AU - Shimano, Yasunobu

AU - Suzuki, Nobuo

AU - Sugiyama, Satoshi

AU - Ogawa, Hiroshi

AU - Kusimoto, Hiroko

AU - Mutoh, Tatsuro

AU - Yuzawa, Yukio

AU - Kitaguchi, Nobuya

PY - 2012/12/1

Y1 - 2012/12/1

N2 - The pathological changes of Alzheimer's disease include the deposition of amyloid β protein (Aβ) as senile plaques in the brain. We hypothesized that the rapid removal of Aβs from the blood may act as a peripheral Aβ drainage sink from the brain. In this study, the plasma Aβ concentrations and the cognitive functions were investigated for in 57 patients on hemodailysis (69.4 ± 3.8 years), 26 renal-failure patients without hemodialysis (66.6 ± 14.7 years), and 17 age-matched healthy controls (66.6 ± 4.1 years). The concentrations of plasma Aβs increased along with the decline of renal functions. Moreover, the renal-failure patients without hemodialysis and with poorer renal functions showed lower cognitive functions. The plasma concentrations of Aβ1-42 correlated with serum creatinine (P < 0.001) and Mini-Mental-State Examination scores (P = 0.017). The dialyzers effectively removed Aβs in the blood during hemodialysis sessions. The plasma Aβ concentrations showed steady or slightly decreasing along with duration of hemodialysis. The total amount of Aβs removed during a hemodialysis session was calculated to be comparable to the Aβs dissolved in the blood and the cerebrospinal fluid. The MMSE scores of the hemodialysis patients showed no clear decrease in longer hemodialysis duration. Therefore, the therapeutic approach for Alzheimer's disease by removing Aβs from the blood is worthy of further investigation, including whether or not Aβs in the brain decrease.

AB - The pathological changes of Alzheimer's disease include the deposition of amyloid β protein (Aβ) as senile plaques in the brain. We hypothesized that the rapid removal of Aβs from the blood may act as a peripheral Aβ drainage sink from the brain. In this study, the plasma Aβ concentrations and the cognitive functions were investigated for in 57 patients on hemodailysis (69.4 ± 3.8 years), 26 renal-failure patients without hemodialysis (66.6 ± 14.7 years), and 17 age-matched healthy controls (66.6 ± 4.1 years). The concentrations of plasma Aβs increased along with the decline of renal functions. Moreover, the renal-failure patients without hemodialysis and with poorer renal functions showed lower cognitive functions. The plasma concentrations of Aβ1-42 correlated with serum creatinine (P < 0.001) and Mini-Mental-State Examination scores (P = 0.017). The dialyzers effectively removed Aβs in the blood during hemodialysis sessions. The plasma Aβ concentrations showed steady or slightly decreasing along with duration of hemodialysis. The total amount of Aβs removed during a hemodialysis session was calculated to be comparable to the Aβs dissolved in the blood and the cerebrospinal fluid. The MMSE scores of the hemodialysis patients showed no clear decrease in longer hemodialysis duration. Therefore, the therapeutic approach for Alzheimer's disease by removing Aβs from the blood is worthy of further investigation, including whether or not Aβs in the brain decrease.

UR - http://www.scopus.com/inward/record.url?scp=84878365343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878365343&partnerID=8YFLogxK

U2 - 10.1007/s00702-012-0844-5

DO - 10.1007/s00702-012-0844-5

M3 - Article

C2 - 22699459

AN - SCOPUS:84878365343

VL - 119

SP - 1533

EP - 1544

JO - Journal of Neural Transmission

JF - Journal of Neural Transmission

SN - 0300-9564

IS - 12

ER -